Cite
HARVARD Citation
Al-Zubaidi, M. et al. (2022). 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma. BMJ open. 12 (4), p. . [Online].